Archive · 27 Aug 2026
FDA Approves Rasonque for Advanced Pancreatic Cancer Treatment
The FDA approved a new medicine called Rasonque for some people with advanced pancreatic cancer.
The medicine is also known as daraxonrasib.
It is for adults whose pancreatic cancer has spread to other parts of the body.
Patients must have already received at least one general cancer treatment.
It may also help patients who cannot receive combination chemotherapy.
The article says a trial found that the drug nearly doubled survival, but it does not give exact numbers.
This approval gives doctors another treatment option for a difficult-to-treat cancer.
The report also mentions promising personalized cancer-vaccine research from Merck and Moderna.
The U.S. Food and Drug Administration approved Rasonque, also called daraxonrasib, for certain adults with advanced pancreatic cancer.
The drug is intended for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment.
It is also approved for patients who cannot take combination chemotherapy.
The article’s headline reports that Rasonque nearly doubled survival in a clinical trial, although no survival figures are provided.
The approval follows recent reports of promising personalized cancer-vaccine trial data from Merck and Moderna.
- Who
- The U.S. Food and Drug Administration approved Rasonque, developed by Revolution Medicines, for eligible adults with metastatic pancreatic adenocarcinoma.
- What
- Rasonque, also known as daraxonrasib, received approval as a targeted treatment for advanced pancreatic cancer.
- When
- The approval was reported after recent cancer-treatment developments; the article does not provide an exact approval date.
- Where
- The approval was issued by the U.S. Food and Drug Administration in the United States.
- Why
- The drug provides another treatment option for adults with metastatic pancreatic cancer after prior treatment or for those unable to take combination chemotherapy.
- Drug
- Rasonque, also known as daraxonrasib
- Developer
- Revolution Medicines
- Regulator
- U.S. Food and Drug Administration
- Approved use
- Metastatic pancreatic adenocarcinoma
- Eligible patients
- Adults who have received at least one prior systemic treatment or cannot take combination chemotherapy
- Reported trial result
- The headline says survival nearly doubled, but the article provides no exact figures